Literature DB >> 2349435

Cytotoxic effects of sera from patients with systemic scleroderma: comparison of three different in vitro methods.

S Majewski1, M Błaszczyk, S Jabłonska, L Rudnicka, M Waşik, A Skiendzielewska, B Makieła.   

Abstract

Sera from 93 patients with systemic scleroderma including incipient or prodromal acroscleroderma and from 43 healthy individuals were studied for cytotoxic effects on endothelial cells by means of three different in vitro methods. Inhibition of 3H-thymidine incorporation by endothelium was caused by about 33% of sera, almost exclusively from patients with diffuse scleroderma and the transitional form: acroscleroderma--diffuse scleroderma. An antibody-dependent cellular cytotoxicity assay revealed cytotoxicity of about 37% of sera from patients with diffuse scleroderma and the transitional form but also of a proportion of sera from patients with CREST syndrome with pronounced vascular changes. Serum cytotoxic activity, revealed by both methods, was related with more frequent involvement of muscle and kidney in the patients. A direct 51Cr release assay showed the cytotoxicity only in 4 of 68 cases in diffuse scleroderma with pronounced internal organ involvement. Thus, depending on the method used, various types of cytotoxicity could be detected in sera from patients with systemic scleroderma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2349435     DOI: 10.1007/bf02274785

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  28 in total

1.  [3H]Thymidine labeling of dermal endothelial cells in scleroderma.

Authors:  R Fleischmajer; J S Perlish
Journal:  J Invest Dermatol       Date:  1977-10       Impact factor: 8.551

2.  Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia. New syndrome.

Authors:  T B Reynolds; E K Denison; H D Frankl; F L Lieberman; R L Peters
Journal:  Am J Med       Date:  1971-03       Impact factor: 4.965

3.  Are endothelial cells stimulated by autoantibodies in scleroderma?

Authors:  E Nunzi; A Rebora
Journal:  Acta Derm Venereol       Date:  1983       Impact factor: 4.437

4.  Human peripheral blood T lymphocyte subpopulations isolated on the basis of their affinity for sheep red blood cells differ in angiogenesis-inducing capability.

Authors:  M J Kamiński; M Nowacyk; E Skopińska-Rozewska; G Kamińska; W Bem
Journal:  Clin Exp Immunol       Date:  1981-11       Impact factor: 4.330

Review 5.  Scleroderma. A model for fibrosis.

Authors:  R Fleischmajer; J S Perlish; M Duncan
Journal:  Arch Dermatol       Date:  1983-12

6.  Pathogenesis of scleroderma. Current concepts.

Authors:  E B Lee; G J Anhalt; J J Voorhees; L A Diaz
Journal:  Int J Dermatol       Date:  1984-03       Impact factor: 2.736

7.  Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis.

Authors:  C A Penning; J Cunningham; M A French; G Harrison; N R Rowell; P Hughes
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

8.  Pathogenesis of scleroderma (systemic sclerosis).

Authors:  E C LeRoy
Journal:  J Invest Dermatol       Date:  1982-07       Impact factor: 8.551

Review 9.  Vascular disease in progressive systemic sclerosis (scleroderma).

Authors:  W L Norton; J M Nardo
Journal:  Ann Intern Med       Date:  1970-08       Impact factor: 25.391

10.  Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus.

Authors:  F Drenk; H Mensing; A Serbin; H Deicher
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

View more
  1 in total

Review 1.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.